Dr Reddy’s hits Amarin with antitrust suit over Vascepa
29-04-2021
T. Schneider / Shutterstock.com
India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone (buprenorphine and naloxone) sublingual film.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Indivior, Dr Reddy’s, generics, Suboxone, opioid addiction, patent infringement, patent validity, settlement
